BTG To Initiate Target Study To Evaluate Dosimetry For HCC Patients

(RTTNews) - BTG plc (BTG) said it plans to initiate the TheraSphere Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment, or TARGET.

The study will evaluate two-compartment dosimetry in hepatocellular carcinoma or HCC patients in interventional oncology in an effort towards a more personalised approach to 90Y radioembolisation therapy for liver cancer patients.

The primary endpoint of the study will determine the correlation between the normal tissue absorbed dose, based on 99mTc-MAA, and =Grade 3 hyperbilirubinemia for patients administered TheraSphere.

BTG plans to initiate the study in July 2016 following IRB and EC approval in the United States and select countries in Europe and Asia.